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A 40-year-old male developed refractory acute promyelocytic leukemia (APL) after various treatments
including all-trans retinoic acid, tamibarotene, arsenic trioxide (As2O3), conventional chemotherapy, and
autologous peripheral blood stem cell transplantation. We attempted to use both tamibarotene and
As2O3 as a combination therapy, and he achieved molecular complete remission. Grade 2 prolongation of the
QTc interval on the electrocardiogram was observed during the therapy. The combination therapy of As2O3
and tamibarotene may be effective and tolerable for treating refractory APL cases who have no treatment
options, even when they have previously been treated with tamibarotene and As2O3 as a single agent.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute promyelocytic leukemia (APL) is driven by an oncogenic
chromosomal translocation fusing the promyelocytic leukemia
(PML) and retinoic acid receptor alpha (RARA) genes. The PML/
RARA fusion protein causes a maturational block at the promye-
locyte stage of myeloid differentiation. Differentiation therapy
with all-trans retinoic acid (ATRA) alone or in combination with
chemotherapy is a major advance in the treatment of APL and is
regarded as the ﬁrst paradigm of molecularly targeted therapy [1].
However, relapse/refractory APL patients demonstrating resistance
to ATRA are recognized as a clinically critical problem.
Arsenic trioxide (As2O3) is also highly effective in the treatment
of APL. Early studies conducted in China and the United States
showed that this agent can induce sustained molecular remission
when used as a single agent in patients who have a relapse after
treatment with ATRA-containing regimens [2,3]. As2O3 acts
through speciﬁc binding of the PML moiety of the disease-speciﬁc
RARA oncoprotein, leading to its degradation and resulting in
partial differentiation and induction of apoptosis of leukemicLtd. This is an open access article u
logy, Ebina General Hospital,
.promyelocytes. Synergy of As2O3 and ATRA, which binds the RARA
moiety of PML/RARA, has been shown at both the biological and
the clinical levels.
On the other hand, tamibarotene is in the same family of drugs
as ATRA, induces the differentiation of APL cells, and is applied to
relapsed cases that have previously received ATRA treatment [4].
Tamibarotene has strong differentiation-inducing activity on hu-
man promyelocytic leukemia cells and is expected to be more ef-
fective and safe than ATRA [5].
While it has been reported that the combination therapy of
As2O3 and ATRA is highly effective not only as the front-line
treatment [6], but also in relapsed and treatment-refractory APL
patients [7], showing fewer adverse events than the combination
of ATRA and chemotherapeutic drugs, the efﬁcacy and tolerability
of the combination of As2O3 and tamibarotene are unknown. We
herein report a patient with APL successfully treated with the
combination therapy of As2O3 and tamibarotene, in whom both
As2O3 and tamibarotene monotherapies had not been effective.2. Case report
A 40-year-old Japanese male was admitted to our hospital be-
cause he presented with purpura on both legs in May 2011. La-
boratory examinations revealed signiﬁcantly abnormal ﬁndings,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Treatment history and outcome prior to combination of As2O3 and tamibarotene.
Phase of treatment Drugs Result of treatment
At initial diagnosis
First induction therapy ATRA, Ara-C, and IDA hCR
Post-remission therapy 1 Ara-C and MIT hCR
Post-remission therapy 2 Ara-C and DNR hCR
Post-remission therapy 3 Ara-C and IDA mCR
Maintenance therapy ATRA Molecular relapse
At ﬁrst molecular relapse
Re-induction therapy 1 Tamibarotene hCR
Re-induction therapy 2 As2O3 hCR
Post-remission therapy 1 As2O3 hCR
Post-remission therapy 2 As2O3 hCR
Post-remission therapy 3 high-dose Ara-C mCR
aPBSCT Bu and MEL mCR
At second molecular relapse
Re-induction therapy Tamibarotene Hematological relapse
ATRA: all-trans retinoic acid, Ara-C: cytarabine, IDA: idarubicin, hCR: hematological
complete remission, MIT: mitoxantrone, DNR: daunorubicin, mCR: molecular
complete remission, aPBSCT: autologous peripheral blood stem cell transplantation,
Bu: busulfan, MEL: melphalan.
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blasts and 22.5% promyelocytes, a hemoglobin level of 12.2 g/dL,
and a platelet count of 20,000/mL. Blood coagulation parameters
showed a ﬁbrinogen level of 154 mg/dL, FDP level of 320.8 mg/mL,
and D-dimer level of 70.9 μg/mL. A bone marrow aspiration study
revealed the proliferation of blasts (65.5%) and promyelocytes
(22.5%). A chromosome analysis based on a G-banding analysis
showed the karyotype 46,XY,t(15;17)(q22;q21) [20/20]. On the
basis of these ﬁndings, a diagnosis of acute promyelocytic leuke-
mia was made. The patient received an induction therapy with
JALSG APL 204 regimen-group C, which consisted of ATRA, cytar-
abine (Ara-C), and idarubicin, and achieved hematological com-
plete remission (CR). Accordingly, he received three cycles of post-
remission therapies and achieved molecular CR (Table 1).
However, although hematological relapse was not detected, the
PML/RARA mRNA transcripts came to be recognized by an RT-PCR
test during the period of maintenance therapy using ATRA. Thus,Fig. 1. Clinical course after second molecular relapse. The patient received the combina
molecular CR on day 28 and on day 61, respectively. APL: acute promyelocytic leukemiathe patient was diagnosed as having molecular relapse and re-
ceived tamibarotene (6 mg/m2/day) for eight weeks, but the PML/
RARA mRNA transcripts did not disappear. He then received a
therapy with JALSG APL 205R regimen composed of As2O3 single
treatment as a re-induction therapy and two cycles of As2O3 single
treatment as post-remission therapy. However, the PML/RARA
mRNA transcripts did not disappear during the following con-
solidation therapy.
He received high-dose cytarabine (2000 mg/m2 twice a day) for
ﬁve days and achieved second molecular CR. Accordingly, auto-
logous peripheral blood stem cell transplantation (aPBSCT) was
performed after the high-dose chemotherapy consisting of bu-
sulfan (1 mg/kg four times a day) for three days and melphalan
(70 mg/m2/day) for two days in August 2014. Engraftment was
subsequently observed and he was discharged while remaining in
molecular CR.
However, a second molecular relapse occurred nine months
after the aPBSCT. Tamibarotene was used again, but resulted in a
hematological relapse.
Then, we attempted to use both tamibarotene and As2O3 as a
combination therapy. He achieved hematological and molecular
CR on day 28 and on day 61, respectively (Fig. 1). Hematologic
toxicities and hypertriglyceridemia were not detected, and grade
2 prolongation of the QTc interval on the electrocardiogram was
observed during the therapy.
Subsequently, the patient underwent allogeneic bone marrow
transplantation in January 2015, and the molecular CR has per-
sisted so far for eleven months since the transplantation.3. Discussion
Reports have included speculation on the molecular mechan-
isms of resistance to ATRA and As2O3. In terms of the mechanism
of resistance to ATRA, genetic mutations (i.e. missense, nonsense,
and deletions) have been identiﬁed on the RARA ligand binding
domain (LBD) in PML-RARA. These mutations accumulate in the
three subregions of the LBD domain [8]. In vitro analyses using
ATRA-resistant NB4 cells and mutated-PML-RARA expressing Cos-1tion chemotherapy of tamibarotene and As2O3. He attained hematological CR and
, WBC: white blood cell, Plt: platelet.
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RARA was lower than that with PML-RARA without mutations
because of conformational changes in LBD. Furthermore, ligand-
dependent N-CoR/SMRT co-repressor release and co-activator re-
cruitment, which are critical for the transcriptional activation of
genes with RARE sites and morphological cell differentiation, are
impaired under the therapeutic dose of ATRA [9].
On the other hand, information on As2O3 resistance remains
limited compared with that on ATRA resistance. Goto et al. re-
ported the ﬁrst molecular basis for clinical resistance to As2O3 in
APL using two As2O3-resistant patients [10]. The authors con-
cluded that PML-B2 domain mutations may play an important role
in aberrant molecular responses to As2O3 and may be critical for
As2O3 resistance in APL.
To overcome these resistance mechanisms in APL cells, a
number of drugs have been tested. Tamibarotene is approximately
10 times more potent than ATRA as an in vitro inducer of differ-
entiation, and is chemically more stable than ATRA [5]. Although
the precise mechanism of the combination of tamibarotene and
As2O3 in overcoming therapy resistance of APL cells is not known,
we suppose a certain synergistic effect of the drugs, as is observed
in the combination of ATRA and As2O3 [6,7]. Most importantly, our
refractory patient, who had previously been treated with both
tamibarotene and As2O3 monotherapies and could not enter he-
matological CR, achieved molecular CR by the combination ther-
apy without severe adverse events, and has been in the molecular
CR although the subsequent allogenic stem cell transplantation
might signiﬁcantly affect the clinical course. The combination of
As2O3 and tamibarotene may be effective and tolerable for treating
patients with refractory APL who have previously received various
treatments including tamibarotene and As2O3, and have no treat-
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